![]() |
|
![]() |
![]() |
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
Sponsors and Collaborators: |
Memorial Sloan-Kettering Cancer Center National Cancer Institute (NCI) American Cancer Society |
Information provided by: | Memorial Sloan-Kettering Cancer Center |
ClinicalTrials.gov Identifier: | NCT00578630 |
The purpose of this study is to develop tests that will allow us to determine who will react differently to the drugs used to treat cancer. We also want to see who will react differently with preparing for a bone marrow transplant.
Condition | Intervention |
Neoplasms |
Other: buccal swabs and obtaining peripheral blood |
MedlinePlus related topics: | Bone Marrow Transplantation Cancer |
Study Type: | Observational |
Study Design: | Case-Only, Prospective |
Official Title: | Interindividual Genetic Variability as a Determinant of Chemotherapy Toxicity and Response in Pediatric Oncology/Bone Marrow Transplantation Patients |
peripheral blood and buccal swab
Estimated Enrollment: | 500 |
Study Start Date: | October 2003 |
Estimated Study Completion Date: | December 2009 |
Estimated Primary Completion Date: | December 2009 (Final data collection date for primary outcome measure) |
Groups/Cohorts | Assigned Interventions |
1
All Pediatric Oncology and Bone Marrow Transplantation Service patients with a histologically proven tumor for whom there is an intent to treat with chemotherapy
|
Other: buccal swabs and obtaining peripheral blood
will be the collection of normal cells and assessments of toxicity following chemotherapy at routine clinic visits.
|
The title of this study is interindividual genetic variability as a determinant of chemotherapy toxicity and response in pediatric oncology/bone marrow transplantation patients. We will collect blood from pediatric oncology/bone marrow transplantation patients who are going to receive chemotherapy in order to assess several defined genetic polymorphisms that may be involved in chemotherapy toxicity and response. The polymorphisms will be assessed on normal mononuclear cells by a combination of techniques. We will determine whether these polymorphisms occur in pediatric oncology/bone marrow transplantation patients and their correlation with different clinical features during and following therapy including toxicity and response. The presence or absence of polymorphisms will be correlated with patient outcome and tumor recurrence.
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Sampling Method: | Non-Probability Sample |
All Pediatric Oncology and Bone Marrow Transplantation Service patients with a histologically proven tumor for whom there is an intent to treat with chemotherapy
Inclusion Criteria:
Exclusion Criteria:
Contact: Paul Meyers, MD | meyersp@mskcc.org |
United States, New York | |||||
Memorial Sloan Kettering Cancer Center | Recruiting | ||||
New York, New York, United States, 10065 | |||||
Contact: Paul Meyers, MD meyersp@mskcc.org | |||||
Principal Investigator: Paul Meyers, MD |
Memorial Sloan-Kettering Cancer Center |
National Cancer Institute (NCI) |
American Cancer Society |
Principal Investigator: | Paul Meyers, MD | Memorial Sloan-Kettering Cancer Center |
Related Info 
![]()   |
Responsible Party: | Memorial Sloan Kettering Cancer Center ( Paul Meyers, MD ) |
Study ID Numbers: | 03-123, NCI CA 83132 |
First Received: | December 19, 2007 |
Last Updated: | June 13, 2008 |
ClinicalTrials.gov Identifier: | NCT00578630 |
Health Authority: | United States: Institutional Review Board |
|
|
![]() |